Pharma engagement shifts from reach to relevance

Tern plc

Pharmaceutical marketing is changing because patients are researching earlier, using more digital channels and arriving at healthcare conversations with stronger opinions about their options.

The effectiveness of pharma engagement is increasingly tied to timing, relevance and message quality. Reaching patients is no longer enough. Companies need to understand what patients are thinking, what concerns are shaping their decisions and where communication can support action.

The original direct-to-consumer and direct-to-patient models still have value, but they do not fully reflect how people now make healthcare decisions. Patients may see social content, read online discussions, use AI tools, compare treatment options and speak to healthcare professionals, all within the same decision-making process. These touchpoints are connected, even if pharma campaigns are often planned separately.

This is where message resonance becomes commercially important. A message works when it reflects what patients actually care about at the moment they need support. That may include confidence, side effects, treatment expectations, cost, access or how to discuss an option with a healthcare professional. Poorly timed or generic content risks being ignored. Relevant messaging can help move patients from interest to informed action.

In markets like this, patients are not waiting passively for information. They are actively shaping their views before they enter clinical conversations. That changes the role of pharma communication from broad awareness to more precise engagement across the full journey.

For life sciences companies, the practical challenge is to connect patient insight with commercial execution. That means understanding the language patients use, the questions they ask and the points where confusion or hesitation appear. It also means aligning patient communication with healthcare professional engagement so that messages are consistent rather than fragmented.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search